Humira, adalimumab
Named-patient access overview. Humira is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
This page is informational, not medical advice. Always work with a licensed treating physician on prescribing decisions.
About Humira
Humira is the brand name for adalimumab, a fully human monoclonal antibody manufactured by AbbVie. The US Food and Drug Administration first approved Humira in December 2002 for rheumatoid arthritis. Over 20+ years it became one of the most-prescribed biologics in the world, with the broadest label of any anti-TNF agent and a deep evidence base across rheumatology, gastroenterology, dermatology, and ophthalmology.
Humira lost US biosimilar exclusivity in 2023, and multiple adalimumab biosimilars are now on the US market at lower price points. The originator Humira remains available, and many treating physicians and patients prefer to stay on the originator molecule when continuity of clinical response matters. Biosimilar substitution rules vary by destination country and by payer.
Mechanism of action
Tumor necrosis factor alpha, or TNF-α, is a master inflammatory cytokine. In autoimmune disease, TNF-α drives joint destruction, gut inflammation, skin plaque formation, and abscess cycles. Adalimumab binds TNF-α directly and prevents it from docking onto its receptors on immune cells. The downstream inflammatory cascade is interrupted.
In plain terms: TNF-α is a megaphone the misfiring immune system uses to amplify itself. Humira pulls the megaphone out of its hand.
FDA-approved indications
The Humira label is unusually broad. Approved US indications include rheumatoid arthritis, juvenile idiopathic arthritis (age 2 and older), psoriatic arthritis, ankylosing spondylitis, Crohn's disease (adult and pediatric), ulcerative colitis (adult and pediatric), plaque psoriasis, hidradenitis suppurativa (age 12 and older), and non-infectious intermediate, posterior, and panuveitis. Age-appropriate indications differ between presentations. Patients should always confirm the current label and the indication that matches their case with their treating physician.
Dosing and administration
Humira is administered as a subcutaneous injection from a prefilled syringe or autoinjector pen. The most common adult regimen is 40 mg every other week. Some indications (Crohn's disease, ulcerative colitis, hidradenitis suppurativa) require a loading regimen of 160 mg at week 0, 80 mg at week 2, then 40 mg every other week starting week 4. Weekly dosing is used in some pediatric and hidradenitis populations. Refrigerated storage between 36 and 46 degrees Fahrenheit is required, with limited room-temperature stability. Self-injection at home is the norm after physician training.
Side-effect profile
The most commonly reported side effects are injection-site reactions, upper respiratory infections, headache, and rash. As an anti-TNF agent, Humira carries a boxed warning for serious infections (including tuberculosis reactivation, invasive fungal infections, and bacterial sepsis) and for malignancies (including lymphoma and other cancers, with a specific signal for hepatosplenic T-cell lymphoma in young patients with inflammatory bowel disease).
Tuberculosis screening before initiation is standard of care. Live vaccines should be avoided while on therapy. Patients with active or chronic hepatitis B, demyelinating disease, congestive heart failure, or active malignancy require careful evaluation before starting. Long-term monitoring and infection vigilance are routine. The right monitoring cadence is always a conversation between patient and treating physician.
Why international patients seek Humira cross-border
Many of the markets Reserve Meds serves have local Humira availability that is either limited to a narrow set of indications, reserved for hospital-only dispensing, or supplied through programs with multi-month waitlists and rationing. Patients with hidradenitis suppurativa, uveitis, pediatric Crohn's, or hidradenitis suppurativa in adolescents frequently find no local route at all, even with a clean US-label indication and a treating physician's prescription.
Some patients also prefer the originator molecule when a stable response on US-sourced Humira is at risk of being disturbed by an involuntary local switch to a biosimilar. Reserve Meds sources Humira from DSCSA-compliant US specialty wholesalers, with full serialization and unbroken cold chain from US warehouse to destination. Every case is physician-led, documented, and routed through the destination country's lawful import framework. We do not handle controlled substances. We do not sell direct to consumers.
Start a request for Humira
Submit a 60-second intake. Our clinical team will review your case and respond as our first cohort opens with case-specific feasibility, a country pathway, an indicative timeline, and a formal quote. Reserved for you.
Access by country
Reserve Meds publishes a detailed country deep-dive for Humira in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.